Roche outlined plans to build autonomous AI-driven labs to accelerate pharmaceutical research and development discovery at its pharma investor day on Monday in Zurich. The company said about 2 billion Swiss francs ($2.41 billion) in R&D savings will be reallocated to programs and productivity initiatives by 2026. Roche aims to bring up to 20 new molecular entities (NMEs), or previously unapproved drug compounds, to market by 2030. Its phase III success rate rose to more than 80% in 2026 year-to-date, compared with 65% in 2025. Aviv Regev, executive vice president of Genentech Research and Early Development, said 40% of pipeline decisions from the fourth quarter of 2025 through the second quarter of 2026 included a tracked AI or computational contribution. Roche expects its Target Nexus AI tool to contribute to 80% of research portfolio decisions by the end of 2026. The company also recently opened its Boston Innovation Center, which will partly focus on AI and machine-learning applications in drug development.